Key factors in the rising cost of new drug discovery and development-Reference-Cited by-同舟云学术

Key factors in the rising cost of new drug discovery and development

Published:2004-05 Issue:5 Volume:3 Page:417-429
ISSN:1474-1776
Container-title:Nature Reviews Drug Discovery
language:en
Short-container-title:Nat Rev Drug Discov

Author:

Dickson Michael,Gagnon Jean Paul

Publisher

Springer Science and Business Media LLC

Subject

Drug Discovery,Pharmacology,General Medicine

Link

http://www.nature.com/articles/nrd1382.pdf

Reference62 articles.

1. Neumann, P. J. Evidence-based and value-based formulary guidelines. Health Affairs 23, 124–134 (2004).

2. American Heart Association. Heart Disease and Stroke Statistics – 2004 Update. American Heart Association [online],(2004).

3. P. L. 102-571, Title I, Section 103. The Prescription Drug User Fee Act of 1992.

4. Kaitin, K. Tufts Center for the Study of Drug Development News Release. [online], < www.csdd.tufts.edu > (2003).

5. Government Accounting Office. Effect of User Fees on Drug Approval Times, Withdrawal, and other Agency Activities. GAO report 02-958, Washington, September 2002 [online], < http://www.gao.gov/new.items/d02958.pdf > (2002).

Cited by 354 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug repositioning by multi-aspect heterogeneous graph contrastive learning and positive-fusion negative sampling strategy;Information Fusion;2024-12

2. Machine learning and natural language processing in clinical trial eligibility criteria parsing: a scoping review;Drug Discovery Today;2024-10

3. Drug discovery in the context of precision medicine and artificial intelligence;Expert Review of Precision Medicine and Drug Development;2024-08-25

4. Drug repositioning based on residual attention network and free multiscale adversarial training;BMC Bioinformatics;2024-08-08

5. GraphCL-DTA: A Graph Contrastive Learning With Molecular Semantics for Drug-Target Binding Affinity Prediction;IEEE Journal of Biomedical and Health Informatics;2024-08